Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.

Clinical pharmacology and therapeutics - 1 Aug 2008

Kim K A, Park P W, Hong S J, Park J-Y

Abstract excerpt

We evaluated the effect of the CYP2C19 genotype on the pharmacokinetics and pharmacodynamcis of clopidogrel. Twenty-four subjects were divided into three groups on the basis of their CYP2C19 genotype: homozygous extensive metabolizers (homoEMs, n = 8), heterozygous EMs (heteroEMs, n = 8), and poor metabolizers (PMs, n = 8). After a single 300-mg loading dose of clopidogrel on day 1, followed by a 75-mg daily...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Blood Platelets

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clopidogrel

Share to Cytochrome P-450 CYP2C19

Share to Drug Administration Schedule

Share to Platelet Aggregation Inhibitors

Share to Ticlopidine

Source

Identifiers

PMID: 18323861
DOI: 10.1038/clpt.2008.20

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.PMID 18323861Read ↗

Study on the effect of CYP2C19 genetic polymorphism and plasma concentration on clopidogrel resistance.Semantic proximity Read ↗

Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects.Semantic proximity Read ↗

Adverse events in cardiovascular disease patients taking clopidogrel: impact of CYP2C19 genotype polymorphismsSemantic proximity Read ↗

The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration.Semantic proximity Read ↗

Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.Semantic proximity Read ↗

Influence of CYP2C19 loss-of-function variants on the metabolism of clopidogrel in patients from north-western China.Semantic proximity Read ↗

Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention.Semantic proximity Read ↗

The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.Semantic proximity Read ↗

Impact of the CYP2C19 Gene Polymorphism on Clopidogrel Personalized Drug Regimen and the Clinical Outcomes.Semantic proximity Read ↗

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.Semantic proximity Read ↗

The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles.Semantic proximity Read ↗

Substantiation of a clopidogrel metabolism-associated gene (CYP2C19) variation among healthy individuals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.